# Who does Johnson & Johnson pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/johnson-johnson · Facet: suppliers · Updated: 2026-09-23T08:29:51.187259+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Johnson & Johnson's confirmed suppliers/cost counterparties include LigaChem Biosciences, Yuhan Corporation plus 2 undisclosed/aggregate relationships. Per the valuechain.wiki graph: 4 cost edges, backed by 12 dated sources, 5 of them primary filings (as of 2026-09-23).

### 인트라셀룰러 테라퓨틱스 (high)
- metric: Amount $14.5B · transaction completed 2025-04-02 · Total consideration transferred for Intra-Cellular Therapies
- note: J&J acquired all outstanding shares of Intra-Cellular Therapies in cash on April 2, 2025. The transaction added CAPLYTA and a central nervous system pipeline to the Innovative Medicine segment.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-11) https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/jnj-20251228.htm: "Total consideration transferred was $14.5 billion."

### 젠맙 (high)
- metric: Amount $2.4B · FY2025 · Reported DARZALEX-related royalties from J&J to Genmab
- note: J&J subsidiary Janssen Biotech holds an exclusive license to Genmab patents used for DARZALEX and pays sales-linked royalties. J&J reported approximately $2.4 billion of Genmab royalties for FY2025; Genmab's filing and Korean brokerage research corroborate the license and royalty structure.
- [confirms] Eugene Investment & Securities (KO, research, published 2026-02-23) https://www.hankyung.com/koreamarket/consensus/pdf/2026-02-f0972e1e7ac529b807eb8a8a25787b1c: "DARZALEX and DARZALEX FASPRO were licensed to J&J and generate royalty income for Genmab."
- [confirms] SEC EDGAR (EN, filing, published 2026-02-17) https://www.sec.gov/Archives/edgar/data/1434265/000143426526000014/gmab-20251231_d2.htm: "J&J is fully responsible for developing and commercializing the licensed products and all costs associated therewith."
- [confirms] SEC EDGAR (EN, filing, published 2026-02-11) https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/jnj-20251228.htm: "Royalty amounts to Genmab were approximately $2.4 billion."

### 리가켐바이오 (high)  → /ligachem-biosciences.md
- metric: Amount $1.7B · LCB84 총 계약규모(마일스톤 포함)
- note: Janssen (J&J) in-licensed worldwide exclusive development and commercialization rights to the Trop2 ADC candidate LCB84 from LigaChem Biosciences in December 2023: up to USD 1.7225bn (USD 100m upfront, USD 200m option exercise, USD 1,422.5m in milestones) plus tiered royalties on net sales.
- [mentions] AJU Business Daily (KO, research, published 2025-12-22) https://www.ajunews.com/view/20251222092821624: "Hyundai Motor Securities raised its target to KRW 240,000 (+60%) on LCB84 indication expansion and platform value."
- [confirms] The Korea Economic Daily (KED Global) (EN, news, published 2023-12-26) https://www.kedglobal.com/bio-pharma/newsView/ked202312260001: "LegoChem Bio and Janssen sign an ADC licensing deal worth up to USD 1.7bn."
- [confirms] DART (FSS) (KO, filing, published 2023-12-26) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20231226900002: "Counterparty: Janssen Biotech, Inc.; total up to USD 1,722,500,000 (KRW 2.246tn) plus royalty — USD 100m upfront, USD 200m option, USD 1,422.5m milestones."
- [mentions] Business Wire (EN, news, published 2023-12-25) https://www.businesswire.com/news/home/20231225841872/en/: "LCB84 applies LigaChem's next-gen ADC platform and a Trop2 antibody licensed from Mediterranea Theranostic; in a Phase 1/2 US trial."

### 유한양행 (high)  → /yuhan.md
- metric: Amount $950M · 총 기술수출 규모(정정)
- note: Janssen (J&J) in-licensed Lazertinib from Yuhan in 2018. The deal is sized at US$950m (revised down from US$1.255bn on 2024-09-20 when the 4th-generation EGFR co-development ended), with a US$50m upfront and milestones. With the Rybrevant plus Lazcluze combination approved in the US (2024-08), Europe (2025-01), Japan (2025-03) and China (2025-07), J&J pays Yuhan royalties on net sales; Yuhan booked KRW 104.1bn of license income in 2025 (4.8% of revenue).
- [confirms] Edaily (Shinhan Securities) (KO, research, published 2026-05-28) https://edaily.co.kr/News/Read?mediaCodeNo=257&newsId=03066806645446296: "Lazertinib running royalty estimated at 10-15% of J&J's Rybrevant+Lazcluze net sales, received quarterly. Shinhan cut its target to KRW 120,000 from 170,000 on softer-than-expected royalties, keeping Buy."
- [mentions] Asiae (KB Securities) (KO, research, published 2026-05-27) https://www.asiae.co.kr/article/2026052715544105667: "KB Securities initiated coverage with Buy and a KRW 125,000 target, expecting royalty inflows to accelerate."
- [confirms] FSS DART (KO, filing, published 2026-03-12) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260312001236: "Janssen Biotech, Inc. ... total deal US$950,000,000, upfront US$50,000,000, milestones incl. US$60m (2024.09), US$15m (2025.05), US$45m (2025.10), plus running royalty on net sales; a portion of fees is shared with originators Oscotec and Genosco."
- [confirms] Johnson & Johnson Investor News (EN, ir, published 2025-05-31) https://www.investor.jnj.com/investor-news/news-details/2025/RYBREVANT-amivantamab-vmjw-plus-LAZCLUZE-lazertinib-prevents-acquired-resistance-versus-osimertinib-in-first-line-EGFR-mutated-non-small-cell-lung-cancer/default.aspx: "RYBREVANT (amivantamab) plus LAZCLUZE (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated NSCLC."

### 레전드바이오텍 (high)
- metric: Market share 50% · Janssen Agreement status at FY2025 · Janssen share of CARVYKTI development, production, and commercialization costs outside Greater China
- note: J&J subsidiary Janssen jointly develops, produces, and commercializes CARVYKTI with Legend Biotech. Outside Greater China, the parties split costs and pre-tax profit or loss equally, and a 2025 supply agreement requires Janssen to pay a cost-plus transfer price for supplied product.
- [confirms] SEC EDGAR (EN, filing, published 2026-03-10) https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/legn-20251231.htm: "We and Janssen will share development, production and commercialization costs and pre-tax profits or losses equally."

Reverse side: https://valuechain.wiki/johnson-johnson/customers.md · Ripple: https://valuechain.wiki/johnson-johnson/ripple.md

---
Full node: https://valuechain.wiki/johnson-johnson.md · JSON: https://valuechain.wiki/johnson-johnson.json